Search for: "The Medicines Company v. Mylan Inc. et al"
Results 21 - 30
of 30
Sorted by Relevance
|
Sort by Date
7 Sep 2011, 4:22 am
Highlights this week included: US: CAFC: Immunisation methods are patent eligible: Classen Immunotherapies, Inc v Biogen IDEC et al (Inventive Step) (Orange Book Blog) (Patently-O) (Patent Docs) (Patent Docs) (IPBiz) (Patent Law Practice Center) (Patent Baristas) US: FTC issues long-awaited final report on authorized generics; report examines both the short-term effects and long-term impact on competition and drug prices (FDA Law Blog) (Orange Book Blog)… [read post]
8 Feb 2011, 10:51 pm
(FDA Law Blog) US: Another academic with solutions to problems that don’t exist (Patent Docs) US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs) US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report) US: District Court New Jersey:… [read post]
6 Jul 2011, 2:21 am
Biopet Vet Lab, Inc., et. al. [read post]
9 Mar 2011, 3:00 am
(Spicy IP) Malta: ‘They shall not pass’ – Maltese court hands down decision in a cross-border seizure case (regarding trade marked pharmaceuticals) against defendant (IPKat) Peru: PIIPA helps get to the root of maca biopiracy (IP tango) US: IP position critical to biotech investment (PatentlyBIOtech) US: Schering files for PTA calculation correction in respect of patent covering ‘Thrombin receptor antagonists’ (Patent Docs) US: Cellectis files patent infringement… [read post]
17 Mar 2020, 1:32 pm
Understanding FDA Recalls of Drugs and Medical Devices An FDA recall of a drug or medical device is the often voluntary action of a company to correct and/or remove a medicine or product from public circulation because it’s in violation of the laws and regulations that the FDA is charged with enforcing. [read post]
27 Jun 2008, 10:04 am
: (The Invent Blog), Impressive work on history of ‘Happy Birthday’ and copyright protection: (Innovationpartners), Gender and copyright: (Patry Copyright Blog) Events 1 July: US PLI: ‘Prior art & obviousness 2008: The PTO and CAFC perspective on patent law sections 102 & 103’ - New York: (Patent Docs), 1-2 July – C5 conference on intellectual asset management for high-tech industries – Paris: (c5-online.com), 2… [read post]
25 Jul 2008, 7:04 am
, (Daily Dose of IP), 26 August: WIPO symposium on IP and multilateral agreements – Geneva: (IPKat), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop – Centurion (South… [read post]
18 Apr 2008, 2:00 am
: (Spicy IP), India: OPPI recommends timeframe for pre-grant opposition: (Spicy IP), India: Jatropha patents (agri-biotech): (Spicy IP), India & US: Stem cell patents: (Spicy IP), Kenya: GSK presses Kenya to crack down on imports of fake medicines: (Afro-IP), Nigeria: Interview with Director General of NAFDAC - Cracking down on counterfeit drugs: (Afro-IP), EU: No link between parallel trade and reduction in R&D, says AG in Sot. [read post]
11 Jul 2008, 4:30 am
: (Spicy IP), India: Ranbaxy-Daiichi deal – Opportunities for private equity companies in India: (Profitability through Simplicity), India: (KEI) Cracking open anti-competitive practices in the developing world: complaints, amendments and waivers: (Spicy IP), India: Is it one rule for Indian pharma companies and another one for those from abroad? [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to dodge real story:… [read post]
